Case study: interstitial lung disease with pulmonary arterial hypertension and COR Pulmonale

Sijina KS; Naga kireeti Seru; Mahima  Mohan; Suberna  basnet; Kumar Amit

doi:10.38022/ajhp.v3i1.71

Sijina KS Department of Pharmacy Practice, Aditya College of Pharmacy, Surampalem, Andhra Pradesh, India
sijinapodimol2@gmail.com
Seru Naga Kireeti Department of Pharmacy Practice, Aditya College of Pharmacy, Surampalem, Andhra Pradesh, India
Mahima Mohan Department of Pharmacy Practice, Aditya College of Pharmacy, Surampalem, Andhra Pradesh, India
Suberna Basnet Department of Pharmacy Practice, Aditya College of Pharmacy, Surampalem, Andhra Pradesh, India
Amit Kumar Department of Pharmacy Practice, Aditya College of Pharmacy, Surampalem, Andhra Pradesh, India

DOI https://doi.org/10.38022/ajhp.v3i1.71

Abstract

Interstitial lung diseases (ILDs) encompass a diverse group of conditions characterized by inflammation and fibrosis of the lung tissue, which can lead to impaired lungs function and respiratory failure. Pulmonary arterial hypertension (PAH) and cor pulmonale are common complications of ILDs, resulting from increased resistance in pulmonary circulation and right heart strain. ILDs and PAH and cor pulmonale are often difficult to diagnoses as the symptoms can be non-specific and overlap with other respiratory diseases. Diagnostic tool such as pulmonary function tests, imaging studies and right heart catheterization are used to establish a definitive diagnosis and assess to disease severity. This case study summarizes the patient case of ILDs with PAH and cor pulmonale, including the underlying pathophysiology, diagnostic tool and management strategies. Additionally, we discuss the challenges in diagnosing and managing ILDs with PAH and cor pulmonale, as well as potential future direction in research and treatment.

Keywords: Interstitial lung disease, Pulmonary arterial hypertension

Downloads

Download data is not yet available.

References

1.American thoracic society clinical cases.
2.Domingo Franco-Palacios, April McDonald, R Neal Aguillard, and Allen BerryBMJ Case Rep. 2017; 2017: bcr2017220659.Published online 2017 Jul 24. doi: 10.1136/bcr-2017-220659David Lederer, MD, and Imre Noth, MD ,Clinical Cases in Interstitial Lung Disease
3.Esam hAlhamad ,CasesJournal volume 2,Article number: 9356 (2009)BMC , Familial interstitial lung disease in four members of one family: a case series
4.Marie, P. Y. Hatron, S. Dominique, P. Cherin, L. Mouthon, and J.-F. Menard, “Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients,” Arthritis & Rheumatism, vol. 63, no. 11, pp. 3439–3447, 2011.
View at: Publisher Site | Google Scholar
5.Marie, S. Josse, P. Y. Hatron et al., “Interstitial lung disease in anti-Jo-1 patients with antisynthetase syndrome,” Arthritis Care & Research, vol. 65, no. 5, pp. 800–808, 2013.
View at: Publisher Site | Google Scholar
6. Nannini, A. J. Jebakumar, C. S. Crowson, J. H. Ryu, and E. L. Matteson, “Primary Sjogren’s syndrome 1976–2005 and associated interstitial lung disease: a population-based study of incidence and mortality,” BMJ Open, vol. 3, Article ID e003569, 2013.
View at: Publisher Site | Google Scholar
7.C. Hyldgaard, O. Hilberg, A. B. Pedersen et al., “A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality,” Annals of the Rheumatic Diseases, vol. 76, no. 10, pp. 1700–1706, 2017.
View at: Publisher Site | Google Scholar
8.A.-M. Hoffmann-Vold, H. Fretheim, A.-K. Halse et al., “Tracking impact of interstitial lung disease in systemic sclerosis in a complete nationwide cohort,” American Journal of Respiratory and Critical Care Medicine, vol. 200, no. 10, pp. 1258–1266, 2019.
View at: Publisher Site | Google Scholar
9.C. Hyldgaard, T. Ellingsen, O. Hilberg, and E. Bendstrup, “Rheumatoid arthritis-associated interstitial lung disease: clinical characteristics and predictors of mortality,” Respiration, vol. 98, no. 5, pp. 455–460, 2019.
View at: Publisher Site | Google Scholar
10.O. Distler, K. B. Highland, M. Gahlemann et al., “Nintedanib for systemic sclerosis-associated interstitial lung disease,” New England Journal of Medicine, vol. 380, no. 26, pp. 2518–2528, 2019.
View at: Publisher Site | Google Scholar
11.K. R. Flaherty, A. U. Wells, V. Cottin et al., “Nintedanib in progressive fibrosing interstitial lung diseases,” New England Journal of Medicine, vol. 381, no. 18, pp. 1718–1727, 2019.
View at: Publisher Site | Google Scholar
12.G. R. Connors, L. Christopher-Stine, C. V. Oddis, and S. K. Danoff, “Interstitial lung disease associated with the idiopathic inflammatory myopathies,” Chest, vol. 138, no. 6, pp. 1464–1474, 2010.
View at: Publisher Site | Google Scholar
13.Fischer, J. J. Swigris, R. M. du Bois et al., “Anti-synthetase syndrome in ANA and anti-Jo-1 negative patients presenting with idiopathic interstitial pneumonia,” Respiratory Medicine, vol. 103, no. 11, pp. 1719–1724, 2009.
View at: Publisher Site | Google Scholar
14.Marie, S. Josse, O. Decaux et al., “Comparison of long-term outcome between anti-Jo1- and anti-PL7/PL12 positive patients with antisynthetase syndrome,” Autoimmunity Reviews, vol. 11, no. 10, pp. 739–745, 2012.
View at: Publisher Site | Google Scholar